Immunacia's Genetic Immunity Reports Phase II Data on DermaVir, a Therapeutic Vaccine for HIV/AIDS, During the XVIII International AIDS Conference: A 70% Viral Load Reduction Demonstrated in HIV Drug-naive Individuals

Published: Jul 19, 2010

BUDAPEST, Hungary & MCLEAN, Va.--(BUSINESS WIRE)--Genetic Immunity, a US/Hungarian biopharmaceutical company developing nanomedicine-based immunotherapies for HIV/AIDS and other chronic diseases, is releasing Phase II data on the Company’s novel DermaVir therapeutic vaccine for HIV/AIDS during the XVIII International AIDS Conference this week in Vienna, Austria. DermaVir, the first dendritic cell-targeting topical HIV vaccine candidate, employs nanotechnology to induce multi-faceted and long-lived immune responses capable of eliminating HIV infected cells.

Back to news